This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Eyes absent homolog 2 (EYA2)	*In vitro* studies suggest selective allosteric inhibitors of EYA2 could help treat breast cancer. A phosphatase assay was used to identify *N*-arylidenebenzohydrazide–based compounds that noncompetitively and reversibly blocked the phosphatase activity of EYA2, which has been associated with increased oncogenic transformation, invasion, migration and metastasis in breast cancer. In human breast cancer cells, one of the EYA2 inhibitors decreased migration compared with vehicle. Next steps include additional efficacy and medicinal chemistry studies on the identified EYA2 inhibitors. Coauthors on the study are scientific founders of SixOne Solutions LLC, which is discovering EYA2 inhibitors to treat breast cancer. *SciBX* 7(21); doi:10.1038/scibx.2014.606 Published online May 29, 2014	Patent applications pending; licensed to SixOne Solutions; available for partnerships	Krueger, A.B. *et al. J. Biol. Chem.*; published online April 22, 2014; doi:10.1074/jbc.M114.566729 **Contact:** Rui Zhao, University of Colorado Denver School of Medicine, Denver, Colo. e-mail: rui.zhao@ucdenver.edu **Contact:** Heide Ford, same affiliation as above e-mail: heide.ford@ucdenver.edu **Contact:** Juan Marugan, National Institutes of Health, Bethesda, Md. e-mail: maruganj@mail.nih.gov